Ortho Clinical Diagnostics is a global leader of in vitro diagnostics dedicated to improving and saving lives through innovative laboratory testing and blood-typing solutions.
Because Every Test is a Life™, Ortho Clinical Diagnostics never stops innovating to offer streamlined, sustainable laboratory solutions that deliver fast, accurate, reliable test results that support exceptional patient care.
As a trusted partner of hospitals, hospital networks, blood banks, and labs around the world, Ortho Clinical Diagnostics serves the clinical laboratory and transfusion medicine communities with customized solutions that enhance clinical outcomes, improve lab performance, overcome staffing challenges and better manage costs.
Ortho Clinical Diagnostics is powered by Ortho Care™, its global, award-winning, holistic approach to service, which supports customers with best-in-class technical support, award-winning field support, and remote service and inventory support.
Company profile
Ticker
OCDX
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Ortho-Clinical Diagnostics Bermuda Co. Ltd.
SEC CIK
Corporate docs
IRS number
981151819
OCDX stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
6 Jun 22
8-K
QuidelOrtho Formed by the Completion of Transaction Combining Quidel and Ortho Clinical Diagnostics
27 May 22
25-NSE
Exchange delisting
27 May 22
8-K
Departure of Directors or Certain Officers
26 May 22
8-K
Regulation FD Disclosure
20 May 22
8-K/A
Submission of Matters to a Vote of Security Holders
20 May 22
8-K/A
Regulation FD Disclosure
19 May 22
8-K
Regulation FD Disclosure
18 May 22
8-K
Other Events
16 May 22
10-Q
2023 Q1
Quarterly report
9 May 22
Latest ownership filings
Financial summary
Quarter (USD) | Apr 22 | Jan 22 | Oct 21 | Jul 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jan 22 | Jan 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 283.00 mm | 283.00 mm | 283.00 mm | 283.00 mm | 283.00 mm | 283.00 mm |
Cash burn (monthly) | 10.17 mm | (no burn) | (no burn) | (no burn) | 1.33 mm | (no burn) |
Cash used (since last report) | 242.29 mm | n/a | n/a | n/a | 31.78 mm | n/a |
Cash remaining | 40.71 mm | n/a | n/a | n/a | 251.22 mm | n/a |
Runway (months of cash) | 4.0 | n/a | n/a | n/a | 188.4 | n/a |
Institutional ownership, Q1 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|